In April 2019, the Ministry of Health, Labor and Welfare's "Guidelines for Sales Information Provision Activities for Medical Drugs" began operation, and it is now required more than ever to create a system and efforts to realize appropriate sales information provision activities. I did. Following the full enforcement from October 4, pharmaceutical and pharmaceutical wholesalers are rapidly responding, but there are major issues in establishing a supervisory system and monitoring huge amounts of data.

Therefore, in December 2019, we will provide a cloud-based application specialized for the life science industry.Veeva Japan Co., Ltd.In collaboration with, we held a seminar to introduce how to solve problems in responding to guidelines, and more than 30 people from the sales information provision activity supervision department, compliance department, information system department, etc. of pharmaceutical companies participated. ..

At the beginning of the seminar, Mr. Hiroaki Uchida, Director of Commercial Japan, Veeva Japan Co., Ltd. explained the interpretation of the new guidelines and the elements and procedures necessary to realize appropriate information provision activities.Next, as an introduction to Veeva solutions that support appropriate monitoring operations with low load, based on support and cases from pharmaceutical companies, prompt response and corrective measures when inappropriate activities are pointed out, future The points of data management were shared with an eye on changes in the guidelines of.

Next, a text from Takumi Saito, Business Solutions Division XNUMX, to solve the issues of monitoring sales information provision activities, such as "comprehensive monitoring," "burden on supervisory work," and "blurring of evaluation criteria and personalization." We introduced a solution using the analysis AI "KIBIT" and an example of significantly reducing the monitoring work man-hours by extracting data that conflicts with the guidelines from MR work records.

At the end of the seminar, we held a cross-talk session with Saori Osumi, Business Solutions Division XNUMX of our company, who has MR experience, and the response policy differs depending on the company, and "Data to be monitored" is the subject of discussion. We exchanged opinions on "definition" and "to have MRs input high-quality information naturally".There were many problems that could not be solved by technology alone, which requires fostering and habituation of corporate culture, and many themes that could not be answered clearly during discussions, but "It was very helpful to hear various views. I received many comments.We would be grateful if we could provide suggestions for discussions and problem solving for each company.

A seminar on the same theme will be held in Osaka on February 2th. (Some contents may be changed)

If you are interested, please join us.

Seminar for pharmaceutical companies "Sales information providedGLSolution and technology utilization for
■ Date: February 2th (Thursday) 20:14 – 30:17
■ Location: 8nd Yoshimoto Building Hilton Plaza West Office Tower 2th floor (XNUMX minutes walk from JR Osaka Station (Sakurabashi Exit))
■ Capacity: 30 name　
■ Participation fee: Free
For details and applicationplease use this form..

◆ GL-compatible solution for sales information provision activities for medical drugs using KIBIT
http://www.kibit-platform.com/solution/mgl-solution/